R3CR Blog2026-10-05T10:48:59-07:00

R3CR Blog

The R3CR Blog is a collaborative space for sharing insights, bridging knowledge gaps, and facilitating dialogue across the cannabis research community. To maintain high standards of evidence-based cannabis and cannabinoid science, all featured content follows strict editorial benchmarks and core research priorities. Our complete publishing standards and guidelines are available here for reference.

Intellectual Property Considerations for Cannabis Research and Innovation

Explore key intellectual property (IP) considerations for cannabis research and innovation. Written by technology transfer expert Michael Shmilovich, this guide covers patent eligibility for formulations and cannabinoid derivatives, plant patents, trade secrets, and genetic resource disclosure requirements to help investigators build a coordinated IP strategy

Modeling the Modern Cannabinoid Formulations

Developing cannabinoids into clinical-grade drug candidates requires navigating significant physicochemical hurdles, including low oral bioavailability, highly variable first-pass metabolism, and chemical instability. In our latest guest article on the R3CR blog, Milind Upadhyay, Chief Executive Officer of Formulaite Inc., examines how mechanistic simulation tools like physiologically based pharmacokinetic (PBPK) modeling and density functional theory (DFT) enable research teams to evaluate formulation behavior and patient variability in silico. He also details how these computational approaches align with current regulatory expectations, including the finalized ICH M15 guidance.

Phytocannabinoids: Regulators Turn to Science

As the FY2026 Agricultural Appropriations Act forces regulators to rely on molecular structures to define hemp, phytocannabinoid compliance is shifting. At R3CR, we translate these complex regulatory updates into validated policy guidance, helping scientists secure DEA registrations and protect the integrity of their clinical investigations.

Cannabis Rescheduling: Implications for Researchers

The federal government is moving to reschedule cannabis from Schedule I to Schedule III, a shift with profound implications for the scientific community. This change streamlines DEA registration and acquisition processes, significantly reducing barriers that have historically impeded clinical research. Explore the regulatory evolution and logistical impacts for licensed researchers.

Disclaimer: The contents of the blogs represent the views of the authors and do not imply endorsement by the R3CR or NIH.

Go to Top